3F-PCP Stats & Data

• Identification and purity: 3‑F‑PCP first appeared in Europe (Slovenia) in late 2020; multiple user communities have since noted batch variability and occasional mislabeling as other PCP analogues (e.g., 3‑Cl‑PCP), making lab‑based drug checking highly advisable. Reagent tests are non‑specific for the class; GC/MS or FTIR is preferable via local drug‑checking services.

• Onset and redosing: Several reports emphasize a slow or uneven come‑up—especially orally/sublingually—so avoid topping up for at least 2–3 hours to prevent accidental overdosing into manic confusion.

• Nasal harm reduction: Insufflation commonly causes severe burn and caustic drip; use finely powdered, tiny test lines, allow long gaps between bumps, and rinse with sterile saline after sessions to reduce tissue damage and epistaxis risk.

• Functional impairment and injury risk: PCP‑class dissociatives can produce profound analgesia, proprioceptive distortion, and overconfidence. Do not cook, drive, swim, or climb during the session and for the entire residual period. Use a sober sitter for strong doses.

• Mental health cautions: High or repeated doses increase risk of acute psychosis‑like states (paranoia, delusions, disinhibition). Individuals with psychosis‑spectrum or bipolar histories should avoid.

• Tolerance/compulsion: Rapid tolerance accrues within a session and over days. Spacing sessions by 10–14 days reduces escalation.

• Hydration and temperature: Maintain gentle hydration and a cool environment; avoid strenuous activity—stimulant‑like activation plus dissociation is associated with overheating and accidents in PCP‑class use.

• IM use is high‑risk: Variable solubility, unknown excipients, and pH can cause tissue injury or abscess; many find IM doses deceptively strong and dysphoric beyond low–moderate ranges. Prefer non‑injecting routes.